Lumida
/CLDX
⌘K
Celldex Therapeutics Inc

Celldex Therapeutics Inc

CLDX
$36.90USD↓-3.15%-1.20 today

MARKET CAP

2.9B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$37 – $39

52W RANGE

$22
$45

AI Summary

Stalk
Sell NowMedium

CLDX has broken decisively below its key support around 38.8–39.4 in a Stage 3 distribution context, confirming supply dominance. Short-term price is extended below declining EMAs with no exhaustion visible, justifying Sell Now into the broken support–turned–resistance zone for continuation participation.

  • ↑Phase 1 CDX-622 delivered dose-dependent, durable serum tryptase reductions.
  • ↑Two Phase 3 barzolvolimab trial readouts in late 2026 could spark stock gains.
  • ↓Profitability remains deeply negative, highlighting ongoing net losses.
Full analysis →
Sales, Adj.
Gross Profit, Adj.
EBITDA, Adj.
EBIT
Net Income